Clinically relevant therapeutic approaches against acetaminophen hepatotoxicity and acute liver failure.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and clinical drug candidates
PubMed 38346541 · doi:10.1016/j.bcp.2024.116056
What was done
This narrative review summarizes the pathophysiological mechanisms of acetaminophen (APAP)-induced hepatotoxicity, evaluating the standard clinical antidote N-acetylcysteine (NAC) alongside emerging therapeutic agents. It covers compounds currently under clinical development (4-methylpyrazole/fomepizole and calmangafodipir), novel mechanistic targets (such as Nrf2 activators), and liver regeneration strategies (including thrombopoietin mimetics, adenosine A2B receptor agonists, and Wharton's Jelly mesenchymal stem cells).
What was found
The abstract reports no quantitative clinical data or effect sizes. It outlines the core toxicological pathway: cytochrome P450 converts APAP into a reactive metabolite that depletes glutathione and binds hepatic protein sulfhydryls. The review reports that several new drug candidates targeting distinct injury and regeneration pathways are progressing through clinical development and may serve as viable adjuncts to standard NAC therapy.
Why it matters
APAP overdose remains a major cause of acute liver failure, and NAC has limited efficacy when treatment is delayed. Translating new mechanistic and regenerative agents into clinical practice could expand treatment options and improve survival in severe or late-presenting overdoses.
Limits
As a narrative review, it presents no original clinical data, systematic search methodology, or quantitative pooling. Evidence for most discussed candidates remains in early clinical development or preclinical stages.
Cited by
- supports N-acetylcysteine (NAC) acts as the antidote to acetaminophen (Tylenol) hepatotoxicity by restoring depleted glutathione levels.